Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Axcynsis Opens Shanghai R&D Center; Raises $15 Million

publication date: Aug 11, 2022

Singapore’s Axcynsis Therapeutics, an ADC company that was formed six months ago, has established an R&D center in Shanghai. During its short life, Axcynsis has changed its name from Tetris and raised $15 million from Trinity Innovation Bioventures Singapore in seed financing to support its Antibody-X Conjugate Synthesis platform. The company says “X” could be any molecule that disrupts abnormal cells. The platform will combine a deep understanding of target biology and proprietary linkers and payloads. It will focus on developing products that target needs in oncology and the immune system. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital